Healthcare Sales & Marketing Network News: Ketoconazole

Searching News Database: Ketoconazole

HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Jul 2023
Viatris Announces Launch of Breyna(TM) (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort(R) for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 13 Jan 2022
PANTHERx Rare(R) Selected by Xeris Pharmaceuticals to Distribute Recorlev(R) (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing's Syndrome
Biopharmaceuticals Distribution

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Oct 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI(R) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
Biopharmaceuticals FDA Licensing

HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Mar 2017
Sonoma Pharmaceuticals Announces Results from SebuDerm(TM) Gel Study in Treatment of Seborrheic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Dec 2015
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R)-Based SebDerm Gel
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 15 May 2015
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
Biopharmaceuticals Acquisitions Licensing Venture Capital

HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Biopharmaceuticals

HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Oct 2014
Cortendo Appoints Robert Lutz as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Aug 2014
Cortendo AB: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Biopharmaceuticals

HSMN NewsFeed - 7 Aug 2014
Cortendo Appoints Matthew Pauls as Chief Executive Officer
Biopharmaceuticals Endocrinology Personnel

HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jun 2014
GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD
Biopharmaceuticals

HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Mar 2014
GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
Biopharmaceuticals

HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 12 Dec 2013
VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia
Biopharmaceuticals Licensing

HSMN NewsFeed - 8 Nov 2013
Eisai Announces Availability of ACIPHEX(R) Sprinkle(TM) (Rabeprazole Sodium) for Treatment of GERD in Children Ages 1 to 11
Biopharmaceuticals Gastroenterology Product Launch

HSMN NewsFeed - 20 Sep 2013
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2013
VIVUS Announces SPEDRA (avanafil) Approval in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 28 Dec 2012
Perrigo Company Acquires Remaining Stake in Cobrek Pharmaceuticals, Inc. for Approximately $45 Million
Biopharmaceuticals Generics Mergers & Acquisitions

HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall

HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 9 Nov 2011
Merck Launches NEXPLANON(R) (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 30 Aug 2011
Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
Biopharmaceuticals Generics Dermatology FDA

HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology

HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 Feb 2011
Covidien Receives FDA Approval for Fentanyl Transdermal System Patch
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA

HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Jun 2010
FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Feb 2010
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors With Plavix(R) (Clopidogrel Bisulfate)
Biopharmaceuticals

HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2009
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 4 May 2009
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Feb 2009
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2009
FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Aug 2008
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 28 Jul 2008
Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 8 Jul 2008
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics to Merge Into Stiefel Laboratories
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 22 May 2008
Barrier Therapeutics Announces Agreement with Procter & Gamble to Market Xolegel (ketoconazole, USP) Gel, 2 Percent With Head & Shoulders Shampoo as Xolegel Duo
Biopharmaceuticals Dermatology

HSMN NewsFeed - 6 May 2008
Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 7 Apr 2008
Stiefel Laboratories Appoints First Chief Scientific Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 29 Feb 2008
Stiefel Laboratories, Inc. Appoints New President
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 10 Dec 2007
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 6 Nov 2007
Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 28 Sep 2007
Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 2 Aug 2007
Barrier Therapeutics Introduces New Xolegel Duo(TM) Offering at the American Academy of Dermatology (AAD) Summer Academy Meeting 2007
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jul 2007
FDA Approves Extina(R) for the Treatment of Seborrheic Dermatitis
Biopharmaceuticals Dermatology Drug Delivery FDA

HSMN NewsFeed - 12 Jul 2007
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Jun 2007
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 21 May 2007
Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 May 2007
Barrier Therapeutics Appoints Dr. Braham Shroot, Dermatology Expert, as New Chief Scientific Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 3 May 2007
Barrier Therapeutics Receives FDA Approval for Solagé(R) Topical Solution Labeling Expansion
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 23 Apr 2007
DiObex Announces the Appointment of David Cory as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2007
Diobex Raises $24 Million Series B Financing Led by Inventages Venture Capital
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 Mar 2007
Barrier Therapeutics Announces Azoline (Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints
Biopharmaceuticals Dermatology

HSMN NewsFeed - 8 Mar 2007
Barrier Therapeutics Receives Regulatory Approval to Market Xolegel(TM) in Canada
Biopharmaceuticals Regulatory Dermatology

HSMN NewsFeed - 6 Mar 2007
Barrier Therapeutics Announces Agreement to Co-Promote Vusion(TM) Ointment to Pediatricians in the United States
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals

HSMN NewsFeed - 3 Nov 2006
Newly-Published Data Showed LEVITRA(R) Treated Erectile Dysfunction Effectively at First Dose In Men With Certain Associated Cardiovascular Conditions
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Dermatology

HSMN NewsFeed - 23 Oct 2006
Connetics Corporation to Merge into Stiefel Laboratories
Biopharmaceuticals Mergers & Acquisitions Dermatology

HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
Biopharmaceuticals Dermatology Drug Delivery FDA

HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Jun 2006
Connetics Names Cynthia Canup Director, Sales Training
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals

HSMN NewsFeed - 8 May 2006
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 55

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 55 additional stories matching:
Ketoconazole
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!